XML 35 R18.htm IDEA: XBRL DOCUMENT v3.25.4
GOODWILL
 12 Months Ended
Dec. 31, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL
NOTE 8 - GOODWILL

The following table reflects the changes in the carrying amount of goodwill by reporting unit for the years ended December 31, 2025 and 2024:

HealthcareIndustrialConsolidated
(in thousands)
Gross Goodwill
Cumulative Impairments
Net GoodwillGross Goodwill
Cumulative Impairments
Net Goodwill
Gross Goodwill
Cumulative Impairments
Net Goodwill
Balance, December 31, 2023$148,137 $(32,055)$116,082 $322,137 $(322,137)$— $470,274 $(354,192)$116,082 
Impairment charge
— (101,445)(101,445)— — — — (101,445)(101,445)
Foreign currency translation adjustments242 — 242 — — — 242 — 242 
Balance, December 31, 2024$148,379 $(133,500)$14,879 $322,137 $(322,137)$— $470,516 $(455,637)$14,879 
Foreign currency translation adjustments696 — 696 — — — 696 — 696 
Balance, December 31, 2025$149,075 $(133,500)$15,575 $322,137 $(322,137)$— $471,212 $(455,637)$15,575 

Interim and Annual Impairment Test During the Year Ended December 31, 2025

During the second quarter of 2025, management identified a triggering event for the Healthcare reporting unit resulting from macroeconomic uncertainties, updates to strategic plans and restructuring initiatives, and a decline in the Company's stock price. Accordingly, an interim goodwill impairment assessment was performed. Based on the results of the quantitative test, no impairment was identified, as the estimated fair value of the reporting unit exceeded its carrying value. We also tested our goodwill for impairment as of our annual impairment testing date, November 1, 2025, and no impairment was identified.

Although no impairment was identified during the interim test and the annual test in 2025, future changes to operating results, cash flows, share price market capitalization, or discount rates could adversely affect the implied fair value of goodwill and may result in future impairment charges.

Impairment of Goodwill During the Year Ended December 31, 2024

During the year ended December 31, 2024, as a result of the significant decline in the trading price of our common stock and our market capitalization as well as reduced long term cash flow forecasts, we performed an interim period quantitative goodwill impairment test as of September 30, 2024, and we recorded a $101.4 million goodwill impairment charge reported within Asset impairment charges on our consolidated statement of operations.

Impairment of Goodwill During the Year Ended December 31, 2023
For the year ended December 31, 2023, we completed the required annual goodwill impairment test for each of our reporting units (Healthcare Solutions and Industrial Solutions) and we determined that the carrying value of our Industrial Solutions reporting unit exceeded its fair value by an amount that was in excess of the goodwill assigned to the Industrial Solutions reporting unit. We recognized a goodwill impairment charge of $279.8 million to write off the entire goodwill balance assigned to the Industrial Solutions reporting unit for the year ended December 31, 2023. This goodwill charge is reported within Asset impairment charges on our consolidated statement of operations.